Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (Emitefur), with other 5-FU-derived drugs or BV-araU (Sorivudine) in rats

Japanese Journal of Pharmacology

Volumn 70, Issue 2, 1996, Pages 139-148

  Miyauchi, Shun ^a   Imaoka, Takeshi ^a   Okada, Tadashi ^a   Motoyama, Masaaki ^a   Kawaguchi, Teruhisa ^a   Akiyama, Hitoshi ^a   Odomi, Masaaki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil derived drug; Emitefur (BOF A2); Leukopenia; Sorivudine (BV araU)

Indexed keywords

2,6 DIHYDROXYNICOTINONITRILE; CARMOFUR; DOXIFLURIDINE; DRUG METABOLITE; EMITEFUR; FLUCYTOSINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; SORIVUDINE; TEGAFUR; UFT; URACIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DECOMPOSITION; DRUG STRUCTURE; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0029965890     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.70.139     Document Type: Article

References (20)

1. Fujii S, Kitano S, Ikenaka K and Shirasaka T: Effect of coadministration of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 70, 209-214 (1979)
2. Spector T, Harrington JA and Porter DJT: 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem. Pharmacol 46, 2243-2248 (1993)
3. Naguib FNM, Hao SN and Kouni MH: Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor 5-benzoyloxybenzyl uracil. Cancer Res 54, 5166-5170 (1994)
4. Porter DJT, Chestnut WG, Taylor LCE, Merrill BM and Spector T: Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil. J Biol Chem 266, 19988-19994 (1994)
5. Tatsumi K, Yamauchi T, Kiyono K, Kishi K, Yanagihara Y, Imaoka T, Kawaguchi T and Kubo M: 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J Biochem 114, 912-918 (1993)
6. Hirohashi M, Kido M, Yamamoto Y, Kojima Y, Jitukawa K and Fujii S: Synthesis of 5-fluorouracil derivatives containing an inhibitor of 5-fluorouracil degradation. Chem Pharm Bull (Tokyo) 41, 1498-1506 (1993)
7. Fujii S, Fukushima M, Shimamoto Y, Oshimo H, Imaoka T and Shirasaka T: Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn J Cancer Res 80, 173-181 (1989)
8. Miyauchi S, Imaoka T, Utsunomiya T, Hayashi K, Kubo M, Kawaguchi T and Matsui Y: Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels. Jpn J Cancer Res 85, 665-668 (1994)
9. Nakai Y, Furuse K, Ohta M, Yamaguchi Y, Fujii M, Asakawa M, Fukuoka M, Yoshida K and Niitani H: Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell cancer. A multicenter phase II study. Acta Oncol 33, 523-526 (1994)
10. David S: Deaths bring clinical trials under scrutiny in Japan. Nature 369, 697 (1994)
11. Fujii S, Shimamoto Y, Ohshimo H, Imaoka T, Motoyama M, Fukushima M and Shirasaka T: Effects of the plasma concentration of 5-fluorouracil and the duration of continous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcoma in rats. Jpn J Cancer Res 80, 167-172 (1989)
12. Moure MA, Stolfi RL and Martin DS: Hematologic effects of interleukin-1 beta, granulocyte colony-stimulating factor, and granulocyte macrophage colony-stimulating factor in tumor-bearing mice treated with fluorouracil. J Natl Cancer Inst 82, 1031-1037(1990)
13. Stolhi RL, Sawyer RC, Nayak R, Spiegelman S and Martin DS: Protection by testosterone from fluorouracil-induced toxicity without loss of anticancer activity against autochthonaus murine breast tumors. Cancer Res 40, 2730-2735 (1980)
14. Desgranges C, Razaka G, Clercq ED, Herdewijn P, Balzarini J, Drouillet F and Bricaud H: Effect of (E)-5-(2-bromovinyl) uracil on the catabolism and antitumor activity of 5-flurorouracil in rats and leukemic mice. Cancer Res 46, 1094-1101 (1986)
15. Kubo M, Sasabe H and Shimizu T: Highly sensitive method for the determination of 5-fluorouracil in biological samples in the presence of 2′-deoxy-5-fluorouridine by gas chromatography-mass spectrometer. J Chromatogr 564, 137-145 (1991)
16. Okayasu T, Sugiyama T and Miyauchi S: Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissue. Jpn J Cancer Res 85, 101-105 (1994)
17. Naguib FNM, Kouni MHK and Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45, 5405-5412 (1985)
18. Ijichi K, Ashida N and Machida H: Effect of 1-β-D-arabinofuranosyl(E)-5(2-bromovinyl)uracil against herpes virus type 1 infection in immunosuppressed mice. Antimicrob Agents Chemother 34, 2431-2433 (1990)
19. Desgranges C, Razaka G, Drouillet F, Bricaud H, Herdewijn P and Clercq ED: Regulation of the antiviral drug (E)-5-(2-bromovinyl)-2′-deoxyuridine in vivo. Nucleic Acids Res 12, 2081-2090 (1984)
20. Ashida N, Ijichi K, Watanabe Y and Machida H: Metabolism of 5′-ether prodrugs of 1-β-D-arabinofuranosyol-E-5-(2-bromovinyl)uracil in rats. Biochem Pharmacol 46, 2201-2207 (1993)